Life Extension Skin Care Sale

Arthritis - Rheumatoid References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Khan F, et al. The role of endothelial function and its assessment in rheumatoid arthritis. Nat Rev Rheumatol. 2010 May;6(5):253-61. Epub 2010 Mar 30.
  2. Radovits BJ, et al. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken), 2010. 62(3):362-70.
  3. Peters MJ, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum, 2009. 61(11): 1571-9.
  4. St. Clair EW, Pisetsky DS, and Haynes BJ. Rheumatoid arthritis 2004, Philadelphia: Lippincott Williams & Wilkins. xiv, p.555.
  5. Klippel, JH. The pocket primer on the rheumatic diseases. 2nd ed2010, Atlanta, GA: Arthritis Foundation. p.242.
  6. Ruffing V and Bingham III CO. Rheumatoid Arthritis Clinical Presentation. Accessed 3/20/12. Available from: http://www.hopkins-arthritis.org/arthritis-info/rheumatoid-arthritis/rheum_clin_pres.html.
  7. NIAMS. Rheumatoid Arthritis. 2009 December 9, 2011]; Available from: http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp.
  8. Cush JJ and Kavanaugh A. Rheumatoid arthritis: early diagnosis and treatment. 1st ed. 2005, West Islip, NY: Professional Communications. p.320.
  9. Mikuls TR, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol, 2007. 34(7):1480-4.
  10. Kahlenberg JM and Fox DA. Advances in the medical treatment of rheumatoid arthritis. Hand Clin, 2011. 27(1):11-20.
  11. Tanasescu C, et al. Endothelial dysfunction in inflammatory rheumatic diseases. Rom J Intern Med. 2009;47(2):103-8.
  12. Spector TD, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ, 1993. 306(6877):558.
  13. Park YB, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol, 1999. 26(8):1701-4.
  14. Boers M, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis, 2003. 62(9):842-5.
  15. van Halm VP, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis, 2007. 66(2): 184-8.
  16. Aletaha D, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum, 2010. 62(9):2569-81.
  17. Pietschmann P. Principles of osteoimmunology: molecular mechanisms and clinical applications 2011, New York: Springer.
  18. American College of Rheumatology Subcommittee on Rheumatic Arthritis Guidelines (2002), Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum, 2002. 46(2):328-46.
  19. Nell VP, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2004. 43(7):906-14.
  20. van Aken J, et al. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis, 2004. 63(3):274-9.
  21. Ma MH, Kingsley GH, and Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford), 2010. 49(1):91-8.
  22. Jurgens MS, Jacobs JW, and Bijlsma JW. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol, 2011. 25(4):523-33.
  23. Life Extension. Available at: http://www.lef.org/HealthWellness/ClinicalResearch/StudyDetails.aspx?study=CL025 Accessed 2/10/2012.
  24. Edwards JC, et al. Efficacy of β-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 2004. 350(25):2572-81.
  25. Keystone E, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis, 2009. 68(2):216-21.
  26. Tak PP and Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther, 2011. 13 Suppl 1:S5.
  27. Moreland LW and O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum, 2002. 46(10):2553-63.
  28. van Gestel AM, et al. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol, 1995. 34(4):347-51.
  29. Cutolo M. Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol. 2011 Aug 2;7(9):500-2. doi: 10.1038/nrrheum.2011.115.
  30. Straub RH, et al. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007 Feb;56(2):399-408.
  31. Buttgereit F, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7):1275-80. Epub 2010 Jun 11.
  32. Buttgereit F. How should impaired morning function in rheumatoid arthritis be treated? Scand J Rheumatol Suppl. 2011;125:28-39.
  33. FDA Import Refusal Report. Available at http://www.accessdata.fda.gov/scripts/importrefusals/ir_detail.cfm?EntryId=UPS-2301487-7&DocId=1&LineId=1&SfxId= Accessed 2/8/2012.
  34. Trelle S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011. 342:c7086.
  35. Faloon W. "ARTHRITIS UPDATE: Drugs That Inhibit COX-2 May Cause Tissue Damage" Life Extension magazine, 1/2001.
  36. Pearson TA, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation, 2002. 106(3):388-91.
  37. Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev, 2011. 11: CD008872.
  38. Sheng X, et al. Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis. J Rheumatol, 2011.
  39. Ridker PM and Solomon DH. Should patients with rheumatoid arthritis receive statin therapy? Arthritis Rheum, 2009. 60(5):1205-9.
  40. Youssef PP, et al. Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum, 1997. 40(8):1400-8.
  41. McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs, 2011. 71(18): 2457-89.
  42. Coblyn JS and Brigham and Women's Hospital. Brigham and Women's experts' approach to rheumatology2011, Sudbury, Mass.: Jones and Bartlett. xi, 236.
  43. Dudics V, et al. Chondrogenic potential of mesenchymal stem cells from patients with rheumatoid arthritis and osteoarthritis: measurements in a microculture system. Cells Tissues Organs, 2009. 189(5):307-16.
  44. Duijnisveld BJ, et al. Regenerative potential of human muscle stem cells in chronic inflammation. Arthritis Res Ther, 2011. 13(6):R207.
  45. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematology Am Soc Hematol Educ Program, 2011. 2011:280-4.
  46. Cutolo M, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13(9):635-8.
  47. Shabanova SS, et al. Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol. 2008 May-Jun;26(3):436-41.
  48. Cutolo M, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006 Nov;1089:538-47.
  49. Masi AT, et al. Sex hormones and risks of rheumatoid arthritis and developmental or environmental influences. Ann N Y Acad Sci. 2006 Jun;1069:223-35.
  50. Karlson EW, et al. A prospective study of androgen levels, hormone-related genes and risk of rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R97. Epub 2009 Jun 25.
  51. Cutolo M. Androgens in rheumatoid arthritis: when are they effectors? Arthritis Res Ther. 2009;11(5):126. Epub 2009 Sep 22.
  52. Weitoft T, et al. Serum levels of sex steroid hormones and matrix metalloproteinases after intra-articular glucocorticoid treatment in female patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Mar;67(3):422-4. Epub 2007 Sep 18.
  53. Weiss EP, et al. droepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011 May;3(5):533-42.
  54. Yukioka M, et al. Adrenocorticotropic hormone and dehydroepiandrosterone sulfate levels of rheumatoid arthritis patients treated with glucocorticoids. Mod Rheumatol. 2006;16(1):30-5.
  55. Goldberg RJ and Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain, 2007. 129(1-2):210-23.
  56. Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. 2011 Oct;44(2):203-15. Epub 2011 Jan 29.
  57. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002. 166(5):608-15.
  58. Dawczynski C, et al. Incorporation of n-3 PUFA and gamma-linolenic acid in blood lipids and red blood cell lipids together with their influence on disease activity in patients with chronic inflammatory arthritis--a randomized controlled human intervention trial. Lipids in health and disease, 2011. 10:130.
  59. Kremer JM, et al. Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet, 1985. 1(8422):184-7.
  60. James MJ and Cleland LG, Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin Arthritis Rheum, 1997. 27(2):85-97.
  61. James M, Proudman S, Cleland L. Fish oil and rheumatoid arthritis: past, present and future. Proc Nutr Soc, 2010. 69(3):316-23.
  62. Caughey GE, et al. Fish oil supplementation increases the cyclooxygenase inhibitory activity of paracetamol in rheumatoid arthritis patients. Complement Ther Med, 2010. 18(3-4):171-4.
  63. Endres S, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med, 1989. 320(5):265-71.
  64. Olendzki BC, et al. Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evid Based Complement Alternat Med, 2011. 2011: Article ID 827286. doi: 10.1155/2011/827286.
  65. Ierna M, et al. Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. BMC musculoskeletal disorders, 2010. 11:136.
  66. Martinez-Calatrava MJ, Largo R, Herrero-Beaumont G. Improvement of experimental accelerated atherosclerosis by chondroitin sulphate. Osteoarthritis Cartilage, 2010. 18 Suppl 1:S12-6.
  67. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med, 1993. 119(9):867-73.
  68. Cameron M, et al. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: Rheumatoid arthritis. Phytother Res, 2009. 23(12):1647-62.
  69. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with blackcurrant seed oil. Br J Rheumatol, 1994. 33(9):847-52.
  70. Macfarlane GJ, et al. Evidence for the efficacy of complementary and alternative medicines in the management of rheumatoid arthritis: a systematic review. Rheumatology (Oxford), 2011. 50(9):1672-83.
  71. Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev, 2011(2):CD002948.
  72. Brzeski M, Madhok R, Capell HA. Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. Br J Rheumatol, 1991. 30(5):370-2.
  73. Gopinath K and Danda D. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis, 2011. 14(4):332-9.
  74. Stoll D, et al. High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. Swiss Med Wkly. 2011 May 27;141:w13196. doi: 10.4414/smw.2011.13196.
  75. Zwerina K, et al. Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis, 2011. 70(6):1122-9.
  76. Cooney JK, et al. Benefits of exercise in rheumatoid arthritis. J Aging Res, 2011. 2011: Article ID 681640. doi: 10.4061/2011/681640.
  77. Chiang EP, et al. Abnormal vitamin B(6) status is associated with severity of symptoms in patients with rheumatoid arthritis. Am J Med, 2003. 114(4):283-7.
  78. Huang SC, et al. Vitamin B(6) supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. Eur J Clin Nutr, 2010. 64(9):1007-13.
  79. Whittle SL and Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford), 2004. 43(3):267-71.
  80. Chiou WF, Chen CF, Lin JJ. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br J Pharmacol. 2000 Apr;129(8):1553-60.
  81. Liu J, Wang ZT, Ji LL. In vivo and in vitro anti-inflammatory activities of neoandrographolide. Am J Chin Med. 2007;35(2):317-28.
  82. Liu J, Wang ZT, Ji LL, Ge BX. Inhibitory effects of neoandrographolide on nitric oxide and prostaglandin E2 production in LPS-stimulated murine macrophage. Mol Cell Biochem. 2007 Apr;298(1-2):49-57.
  83. Liu J, Wang ZT, Ge BX. Andrograpanin, isolated from Andrographis paniculata, exhibits anti-inflammatory property in lipopolysaccharide-induced macrophage cells through down-regulating the p38 MAPKs signaling pathways. Int Immunopharmacol. 2008 Jul;8(7):951-8.
  84. Bao Z, Guan S, Cheng C, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. Am J Respir Crit Care Med. 2009 Apr 15;179(8):657-65.
  85. Ahn KS, Aggarwal BB. Transcription Factor NF-{kappa}B: A sensor for smoke and stress signals. Ann N Y Acad Sci. 2005 Nov;1056:218-33.
  86. Chao WW, Kuo YH, Hsieh SL, Lin BF. Inhibitory effects of ethyl acetate extract of Andrographis paniculata on NF-{kappa}B trans-activation activity and LPS-induced acute inflammation in mice. Evid Based Complement Alternat Med. 2009 Sep 10.
  87. Naik SR, Hule A. Evaluation of immunomodulatory activity of an extract of andrographolides from Andographis paniculata. Planta Med. 2009 Jun;75(8):785-91.
  88. Manganelli P and Rioda WT. [Weekly low-dose methotrexate in rheumatoid arthritis. Review of the literature]. Minerva medica, 1993. 84(10):541-52.
  89. Jackson JK, et al. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res, 2006. 55(4):168-75.
  90. Henrotin Y, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage, 2010. 18(2):141-9.
  91. Buhrmann C, et al. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther, 2010. 12(4):R127.
  92. Banji D, et al. Synergistic activity of curcumin with methotrexate in ameliorating Freund's Complete Adjuvant induced arthritis with reduced hepatotoxicity in experimental animals. Eur J Pharmacol, 2011. 668(1-2):293-8.
  93. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res, 1980. 71:632-4.
  94. Chandran B and Goel A. A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Published online 9 MAR 2012.
  95. Lee JH and Kim GH. Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. J Food Sci, 2010. 75(7):H212-7.
  96. Natarajan V, et al. Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis. J Pharm Sci, 2011. 100(1):195-205.
  97. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med, 2006. 72(12):1100-16.
  98. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet, 2011. 50(6):349-69.
  99. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin Against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci. 2010;7(6):366–377
  100. Sengupta K, et al. Cellular and molecular mechanisms of anti-inflammatory effect of Aflapin: a novel Boswellia serrata extract. Mol Cell Biochem, 2011. 354(1-2):189-97.
  101. Shukla M, et al. Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition, 2008. 24(7-8):733-43.
  102. Balbir-Gurman A, et al. Consumption of pomegranate decreases serum oxidative stress and reduces disease activity in patients with active rheumatoid arthritis: a pilot study. Isr Med Assoc J, 2011. 13(8):474-9.
  103. Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther, 2010. 12(2):208.
  104. Kim HR, et al. Green tea protects rats against autoimmune arthritis by modulating disease-related immune events. J Nutr, 2008. 138(11):2111-6.
  105. Haqqi TM, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A, 1999. 96(8):4524-9.
  106. Grzanna R, Lindmark L, Frondoza CG. Ginger--an herbal medicinal product with broad anti-inflammatory actions. J Med Food, 2005. 8(2):125-32.
  107. Nievergelt A, et al. Ginger phenylpropanoids inhibit IL-1beta and prostanoid secretion and disrupt arachidonate-phospholipid remodeling by targeting phospholipases A2. J Immunol, 2011. 187(8):4140-50.
  108. Funk JL, et al. Comparative effects of two gingerol-containing Zingiber officinale extracts on experimental rheumatoid arthritis. J Nat Prod, 2009. 72(3):403-7.
  109. Ramadan G, Al-Kahtani MA, El-Sayed WM. Anti-inflammatory and anti-oxidant properties of Curcuma longa (turmeric) versus Zingiber officinale (ginger) rhizomes in rat adjuvant-induced arthritis. Inflammation, 2011. 34(4):291-301.
  110. Fouda AM and Berika MY. Evaluation of the effect of hydroalcoholic extract of Zingiber officinale rhizomes in rat collagen-induced arthritis. Basic Clin Pharmacol Toxicol, 2009. 104(3):262-71.
  111. Tekeoglu I, et al. Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res. 2007 Sep;21(9):895-7.
  112. Gheita TA and Kenawy SA. Effectiveness of Nigella sativa Oil in the Management of Rheumatoid Arthritis Patients: A Placebo Controlled Study. Phytother Res, 2011.
  113. Ju YH, et al. beta-Sitosterol, beta-Sitosterol Glucoside, and a Mixture of beta-Sitosterol and beta-Sitosterol Glucoside Modulate the Growth of Estrogen-Responsive Breast Cancer Cells In Vitro and in Ovariectomized Athymic Mice. J Nutr. 2004 May;134(5):1145-51.
  114. [Anonymous] Monograph. Plant sterols and sterolins. Altern Med Rev. 2001 Apr;6(2):203-6.
  115. Bouic P, et al. The effects of B-sitosterol (BSS) and B-sitosterol glucoside (BSSG) mixture on selected immune parameters of marathon runners: inhibition of post marathon immune suppression and inflammation. Int J Sports Med. 1999 May;20(4):258-62.
  116. Louw I, et al. A pilot study of the clinical effects of a mixture of beta-sitosterol and beta-sitosterol glucoside in active rheumatoid arthritis (RA). Am J Clin Nutr 2002 75: 2 339S-439S [abstract 40].
  117. Talbott SM and Hughes K. The health professional's guide to dietary supplements2007, Philadelphia: Lippincott Williams & Wilkins. xx, p.444.
  118. Rutjes AW, et al. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev, 2009(4):CD007321.
  119. Soeken KL, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract, 2002. 51(5):425-30.
  120. Nesher G, Osborn TG, Moore TL. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol, 1996. 14(4):395-9.
  121. Hua J, et al. Evaluation of the suppressive actions of glucosamine on the interleukin-1beta-mediated activation of synoviocytes. Inflamm Res, 2007. 56(10):432-8.
  122. Nakamura H, et al. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int, 2007. 27(3):213-8.
  123. Van den Ende CH, et al. Dynamic exercise therapy in rheumatoid arthritis: a systematic review. Br J Rheumatol, 1998. 37(6):677-87.
  124. Cairns AP and McVeigh JG. A systematic review of the effects of dynamic exercise in rheumatoid arthritis. Rheumatol Int, 2009. 30(2):147-58.
  125. Plasqui G. The role of physical activity in rheumatoid arthritis. Physiol Behav, 2008. 94(2):270-5.
  126. Flint-Wagner HG, et al. Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients. J Clin Rheumatol, 2009. 15(4):165-71.
  127. van de Laar MA, et al. Food intolerances in rheumatoid arthritis. I. A double blind, controlled trial of the clinical effects of elimination of milk allergens and azo dyes. Ann Rheum Dis. 1992 Mar;51(3):298-302.
  128. Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.
  129. Cremer MA, Rosloniec EF, Kang AH. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med (Berl). 1998 Mar;76(3-4):275-88.
  130. Park KS, Park MJ, Cho ML, et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol. 2009;19(6):581-9.
  131. Zhu P, Li XY, Wang HK, et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol. 2007 Jan;122(1):75-84.
  132. Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6.
  133. Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer’s patches during the induction of oral tolerance in type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 2006 Mar;54(3):887-98.